Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 2, Issue , 2016, Pages 27-38

  Racine, Annie M ^a,b   Koscik, Rebecca L ^a   Nicholas, Christopher R ^a,c   Clark, Lindsay R ^a   Okonkwo, Ozioma C ^a,c   Oh, Jennifer M ^a,c   Hillmer, Ansel T ^a,d   Murali, Dhanabalan ^a   Barnhart, Todd E ^a   Betthauser, Tobey J ^a   Gallagher, Catherine L ^a,c   Rowley, Howard A ^a   Dowling, N Maritza ^a,c   Asthana, Sanjay ^a,c   Bendlin, Barbara B ^a,c   Blennow, Kaj ^f   Zetterberg, Henrik ^e,f   Carlsson, Cynthia M ^a,c   Christian, Bradley T ^a,d   Johnson, Sterling C ^a,c,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; A 42; Biological parametric mapping; Biomarkers; Cerebrospinal fluid; Linear mixed effects; MCP 1; NFL; PET; PiB; Preclinical AD; Tau; YKL 40

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; PITTSBURGH COMPOUND B; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LONGITUDINAL STUDY; MALE; MEMORY TEST; MIDDLE AGED; NERVOUS SYSTEM INJURY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POPULATION RISK; PROTEIN CEREBROSPINAL FLUID LEVEL; TEMPORAL CORTEX;

EID: 84957990414     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.11.006     Document Type: Article

References (54)

1. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
2. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
3. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013, 12:357-367.
4. Blennow K., Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2009, 18:413-417.
5. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
6. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10:698-712.
7. Hardy J.A., Higgins G.A. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992, 256:184-185.
8. Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 2015, 18:794-799.
9. Chetelat G. Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat Rev Neurol 2013, 9:123-124.
10. Davis D.G., Schmitt F.A., Wekstein D.R., Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999, 58:376-388.
11. Perez-Nievas B.G., Stein T.D., Tai H.C., Dols-Icardo O., Scotton T.C., Barroeta-Espar I., et al. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 2013, 136:2510-2526.
12. Musiek E.S., Holtzman D.M. Three dimensions of the amyloid hypothesis: Time, space and 'wingmen'. Nat Neurosci 2015, 18:800-806.
13. Bright J., Hussain S., Dang V., Wright S., Cooper B., Byun T., et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015, 36:693-709.
14. Lista S., Garaci F.G., Ewers M., Teipel S., Zetterberg H., Blennow K., et al. CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimers Dement 2014, 10:381-392.
15. Blennow K., Dubois B., Fagan A.M., Lewczuk P., de Leon M.J., Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 2015, 11:58-69.
16. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144.
17. Sager M.A., Hermann B., La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 2005, 18:245-249.
18. Johnson S.C., Christian B.T., Okonkwo O.C., Oh J.M., Harding S., Xu G., et al. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiol Aging 2014, 35:576-584.
19. Bendlin B.B., Carlsson C.M., Johnson S.C., Zetterberg H., Blennow K., Willette A.A., et al. CSF T-Tau/Abeta42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One 2012, 7:e37720.
20. Sprecher KE, Bendlin BB, Racine AM, Okonkwo OC, Christian BT, Koscik RL, et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging 2015, 36:2568-2576.
21. Lezak M.D. Neuropsychological assessment 2004, Oxford University press, New York, New York. 4th ed.
22. Spreen O., Strauss E. A compendium of neuropsychological tests: Administration, norms, and commentary 1998, Oxford University Press, USA.
23. Schmidt M. Rey auditory verbal learning test: A handbook 1996, Western Psychological Services, Los Angeles, CA.
24. Wechsler Wechsler memory scale-revised 1987, The Psychological Corporation, Harcourt Brace Jovanovich, inc for Psychological Corp, New York.
25. Curran-Everett D. Multiple comparisons: Philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1-R8.
26. Locascio J.J., Atri A. An overview of longitudinal data analysis methods for neurological research. Dement Geriatr Cogn Dis Extra 2011, 1:330-357.
27. Senn S., Stevens L., Chaturvedi N. Repeated measures in clinical trials: Simple strategies for analysis using summary measures. Stat Med 2000, 19:861-877.
28. Casanova R., Srikanth R., Baer A., Laurienti P.J., Burdette J.H., Hayasaka S., et al. Biological parametric mapping: A statistical toolbox for multimodality brain image analysis. Neuroimage 2007, 34:137-143.
29. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
30. Li S., Pu F., Shi F., Xie S., Wang Y., Jiang T. Regional white matter decreases in Alzheimer's disease using optimized voxel-based morphometry. Acta Radiol 2008, 49:84-90.
31. Sutphen C.L., Jasielec M.S., Shah A.R., Macy E.M., Xiong C., Vlassenko A.G., et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 2015, 72:1029-1042.
32. Buckner R.L., Sepulcre J., Talukdar T., Krienen F.M., Liu H., Hedden T., et al. Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009, 29:1860-1873.
33. Simic G., Babic M., Borovecki F., Hof P.R. Early failure of the default-mode network and the pathogenesis of Alzheimer's disease. CNS Neurosci Ther 2014, 20:692-698.
34. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
35. Neill D. Should Alzheimer's disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence. Ageing Res Rev 2012, 11:104-122.
36. Fjell A.M., McEvoy L., Holland D., Dale A.M., Walhovd K.B. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol 2014, 117:20-40.
37. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005, 25:7709-7717.
38. Skoog I., Davidsson P., Aevarsson O., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003, 15:169-176.
39. Molinuevo J.L., Blennow K., Dubois B., Engelborghs S., Lewczuk P., Perret-Liaudet A., et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2014, 10:808-817.
40. Lewczuk P., Lelental N., Spitzer P., Maler J.M., Kornhuber J. Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays. J Alzheimers Dis 2015, 43:183-191.
41. De Meyer G., Shapiro F., Vanderstichele H., Vanmechelen E., Engelborghs S., De Deyn P.P., et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010, 67:949-956.
42. Duits F.H., Teunissen C.E., Bouwman F.H., Visser P.J., Mattsson N., Zetterberg H., et al. The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. Alzheimers Dement 2014, 10:713-723.e2.
43. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 2007, 24:118-124.
44. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343-349.
45. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012, 69:98-106.
46. Ishizuka K., Kimura T., Igata-yi R., Katsuragi S., Takamatsu J., Miyakawa T. Identification of monocyte chemoattractant protein-in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 1997, 51:135-138.
47. Galimberti D., Schoonenboom N., Scarpini E., Scheltens P. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol 2003, 53:547-548.
48. Westin K., Buchhave P., Nielsen H., Minthon L., Janciauskiene S., Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012, 7:e30525.
49. Lautner R., Mattsson N., Scholl M., Augutis K., Blennow K., Olsson B., et al. Biomarkers for microglial activation in Alzheimer's disease. Int J Alzheimers Dis 2011, 2011:939426.
50. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
51. Buchhave P., Blennow K., Zetterberg H., Stomrud E., Londos E., Andreasen N., et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 2009, 4:e6294.
52. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol 1998, 44:17-26.
53. Okonkwo O.C., Oh J.M., Koscik R., Jonaitis E., Cleary C.A., Dowling N.M., et al. Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. J Int Neuropsychol Soc 2014, 20:422-433.
54. Stomrud E., Hansson O., Zetterberg H., Blennow K., Minthon L., Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 2010, 67:217-223.